Picture loading failed.

Anti-RSV gpF therapeutic antibody (Pre-made Palivizumab biosimilar,Whole mAb) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Palivizumab, sold under the brand name Synagis, is a monoclonal antibody produced by recombinant DNA technology used to prevent severe disease caused by respiratory syncytial virus (RSV) infections. It is recommended for infants that are high-risk because of prematurity or other medical problems such as congenital heart disease.

Order information


Delivery impact due to the Coronavirus Outbreak

With the COVID-19 outbreak in the world, many flights have been cancelled. In order for the customer to receive the goods properly, we use the FedEx Customized Freight (FCF) of Fedex which demands a higher fee. If the delivery fee is more expensive in your area, we will contact you by mail.

Catalog No. Package Price(In USD) Qty (Quantity) Sum(In USD)
GMP-Bios-ab-423-1mg 1mg 3090
GMP-Bios-ab-423-10mg 10mg 21890
GMP-Bios-ab-423-100mg 100mg 148000
GMP-Bios-ab-423-xmg >100mg Inquiry
Shipping Cost: 760.00
Total:



Description

Products Name (INN Index) Anti-RSV gpF therapeutic antibody (Pre-made Palivizumab biosimilar,Whole mAb)
INN Name Palivizumab
TargetRSV gpF
FormatWhole mAb
DerivationHumanized
Species ReactivityHuman
CH1 IsotypeIgG1
VD LCKappa
Highest_Clin_Trial (Jan '20)Approved
Est. StatusNFD
100% SI StructureNone
99% SI Structure2hwz:HL
95-98% SI StructureNone
Year Proposed1998
Year Recommended1999
CompaniesMedImmune
Conditions ApprovedRespiratory syncytial virus infections
Conditions Activena
Conditions Discontinuedna
Development TechGS Gene Expression System